{
    "Rank": 442,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT01964027",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "SIEG"
                },
                "Organization": {
                    "OrgFullName": "Anhui Medical University",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer",
                "OfficialTitle": "The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer",
                "Acronym": "SIEG"
            },
            "StatusModule": {
                "StatusVerifiedDate": "October 2013",
                "OverallStatus": "Unknown status",
                "LastKnownStatus": "Not yet recruiting",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "October 2013"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "July 2014",
                    "PrimaryCompletionDateType": "Anticipated"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "December 2014",
                    "CompletionDateType": "Anticipated"
                },
                "StudyFirstSubmitDate": "January 19, 2012",
                "StudyFirstSubmitQCDate": "October 14, 2013",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "October 17, 2013",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "October 14, 2013",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "October 17, 2013",
                    "LastUpdatePostDateType": "Estimate"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Pan Yueyin",
                    "ResponsiblePartyInvestigatorTitle": "Professor",
                    "ResponsiblePartyInvestigatorAffiliation": "Anhui Medical University"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Anhui Medical University",
                    "LeadSponsorClass": "OTHER"
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "This study is to determine the response rate and safety profile of irinotecan plus epirubicin as the second-line chemotherapy for advanced gastric cancer and fully evaluate the feasibility and effectiveness of the regime.",
                "DetailedDescription": "The main purposes: to determine the progression-free survival (PFS) and overall survival (OS) of gastric cancer patients given irinotecan + epirubicin as second-line treatment, who are at Stage IV with disease progressed or recurred after first-line chemotherapy failed, ,\n\nThe Secondary purposes: to determine disease control rate (Disease Control Rate, DCR), the objective response rate (Object Response rate, ORR) and the Quality of life (Quality Of Life, QOL)"
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Stage IV Gastric Cancer With Metastasis"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "second line chemoregime",
                        "gastric cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "40",
                    "EnrollmentType": "Anticipated"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Irinotecan plus epirubicin",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Irinotecan(Camptosar)150mg /m2 d1,\uff08intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment * 6 cycles as the second line chemoregime for advanced gastric cancer",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: second line chemoregime for advanced gastric cancer"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "second line chemoregime for advanced gastric cancer",
                            "InterventionDescription": "Irinotecan(Camptosar)150mg /m2 d1,\uff08intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment * 6 cycles as the second line chemoregime for advanced gastric cancer",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Irinotecan plus epirubicin"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "irinotecan plus epirubicin"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "PFS and OS",
                            "PrimaryOutcomeDescription": "Evaluation progression-free survival (PFS) and overall survival (OS)\n\nRECIST(Response Evaluation Criteria In Solid Tumors)1.1:\n\nComplete response (CR)\nPartial response (PR)\nStable disease(SD) and progression disease(PD)\nCR + PR is efficient.",
                            "PrimaryOutcomeTimeFrame": "2 years"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion criteria:\n\nAged between 18 to 70 years\nThe pathologically confirmed gastric adenocarcinoma and the failure of first-line chemotherapy\nMeasurable lesions outside the stomach\nECOG(Eastern Cooperative Oncology Group ) score between 0 to 1\nExpected survival time of at least 3 months\nSubjects receiving treatment for other damage caused has been restored, which it accepted the nitroso or mitomycin interval> 6 weeks, the acceptance of other cytotoxic drugs, radiotherapy or surgery> = 4 weeks, and the wound has completely healed. No bleeding, no nervous system transferred\nBlood and organ function was normal\n\nExclusion criteria:\n\nComorbid with other malignant tumors\nPregnant and lactating women\nwith the disease of endangering patient's safety and affecting the completion of the study\nPatients suffering from high blood pressure by antihypertensive treatment cannot control (systolic blood pressure> 140mmhg, diastolic blood pressure> 90mmhg,) there is more than Class I and Class I arrhythmia coronary heart disease, with more than Class I heart dysfunction\nMajor organ failure, such as decompensated heart and lung failure, liver failure, renal failure and patients with intestinal obstruction ipate in other clinical trials of patients in the past four weeks\nParticipated in clinical trials with other drugs or using other drugs during past 4 weeks\nLesions which can't be measured such as pleural effusion, ascites, peritoneal cancer lesions, diffuse liver and bone metastases violation, brain metastasis",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "MaximumAge": "75 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "CentralContactList": {
                    "CentralContact": [
                        {
                            "CentralContactName": "Yueyin Pan, MD",
                            "CentralContactRole": "Contact",
                            "CentralContactPhone": "865512922987",
                            "CentralContactEMail": "yueyinpan@gmail.com"
                        }
                    ]
                },
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Yueyin Pan, MD",
                            "OverallOfficialAffiliation": "The First Affiliated Hospital of Anhui Medical University",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Department of Oncology,The First Affiliated Hospital of Anhui Medical University",
                            "LocationCity": "Hefei",
                            "LocationState": "Anhui",
                            "LocationZip": "230032",
                            "LocationCountry": "China",
                            "LocationContactList": {
                                "LocationContact": [
                                    {
                                        "LocationContactName": "Yueyin Pan, MD",
                                        "LocationContactRole": "Contact",
                                        "LocationContactPhone": "865512922987",
                                        "LocationContactEMail": "yueyinpan@gmail.com"
                                    },
                                    {
                                        "LocationContactName": "Hu Liu, MD",
                                        "LocationContactRole": "Sub-Investigator"
                                    }
                                ]
                            }
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000013274",
                            "ConditionMeshTerm": "Stomach Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000005770",
                            "ConditionAncestorTerm": "Gastrointestinal Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000004067",
                            "ConditionAncestorTerm": "Digestive System Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000004066",
                            "ConditionAncestorTerm": "Digestive System Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000005767",
                            "ConditionAncestorTerm": "Gastrointestinal Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000013272",
                            "ConditionAncestorTerm": "Stomach Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M11997",
                            "ConditionBrowseLeafName": "Neoplasm Metastasis",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15754",
                            "ConditionBrowseLeafName": "Stomach Neoplasms",
                            "ConditionBrowseLeafAsFound": "Gastric Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M8576",
                            "ConditionBrowseLeafName": "Gastrointestinal Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M6946",
                            "ConditionBrowseLeafName": "Digestive System Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M6945",
                            "ConditionBrowseLeafName": "Digestive System Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8573",
                            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15752",
                            "ConditionBrowseLeafName": "Stomach Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "T5486",
                            "ConditionBrowseLeafName": "Stomach Cancer",
                            "ConditionBrowseLeafAsFound": "Gastric Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC06",
                            "ConditionBrowseBranchName": "Digestive System Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "Rare",
                            "ConditionBrowseBranchName": "Rare Diseases"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000077146",
                            "InterventionMeshTerm": "Irinotecan"
                        },
                        {
                            "InterventionMeshId": "D000015251",
                            "InterventionMeshTerm": "Epirubicin"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000059004",
                            "InterventionAncestorTerm": "Topoisomerase I Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000059003",
                            "InterventionAncestorTerm": "Topoisomerase Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000004791",
                            "InterventionAncestorTerm": "Enzyme Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        },
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000000903",
                            "InterventionAncestorTerm": "Antibiotics, Antineoplastic"
                        },
                        {
                            "InterventionAncestorId": "D000059005",
                            "InterventionAncestorTerm": "Topoisomerase II Inhibitors"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M1671",
                            "InterventionBrowseLeafName": "Irinotecan",
                            "InterventionBrowseLeafAsFound": "Conventional",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M17644",
                            "InterventionBrowseLeafName": "Epirubicin",
                            "InterventionBrowseLeafAsFound": "Reduced",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M29039",
                            "InterventionBrowseLeafName": "Topoisomerase I Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M7641",
                            "InterventionBrowseLeafName": "Enzyme Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3912",
                            "InterventionBrowseLeafName": "Anti-Bacterial Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3914",
                            "InterventionBrowseLeafName": "Antibiotics, Antitubercular",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "Infe",
                            "InterventionBrowseBranchName": "Anti-Infective Agents"
                        }
                    ]
                }
            }
        }
    }
}